Antimicrobial peptide that inhibits many reference strains of bacteria and fungi (PubMed:23638903, PubMed:30269852). Is potent against Candida species and multidrug-resistant Acinetobacter baumannii (MDRAB) (PubMed:25199777, PubMed:30269852). Is probably localized in the cytoplasm after being transported through the cell wall and membrane (PubMed:30269852). Is able to interact with cell membranes and enter into cell plasma to activate the mitochondrial death pathway to sensitize cancer cells for apoptosis, as well as up-regulates p27 to inhibit cell proliferation (PubMed:22882120). It shows very low effect on normal cells, such as erythrocytes, Hek293t cells (PubMed:22882120). It also potently inhibits tumor cell growth in vitro, and suppresses various tumor growth in vivo when tested in human cancer xenograft models (PubMed:22882120). It interacts with the cell membrane and is then internalized into the cytoplasm of cancer cells to initiate the programmable cell death (PubMed:22882120). In addition, this peptide has the therapeutic effects of anti-hypertension by endothelium-dependent vasodilatation via the NO/sGC/cGMP signaling pathway (PubMed:29248696). In vivo, this peptide also shows a significant ability to inhibit T.gondii invasion and proliferation, making it a potential alternative agent for the treatment of toxoplasmosis (PubMed:30682337). Monomer in solution. Small size oligomers on the lipid membranes. Lipid membranes induce the formation of amphipathic-helix conformation of lycosin-I and subsequently stable aggregates of peptide molecules on bilayer, which are believed to be crucial for the cell penetrating ability of lycosin-I. When conjugated to gold nanoparticles (LGNPs) or gold nanorods (LGNRs), this peptide has great potential in cancer-targeting delivery and photothermal therapy. Belongs to the cationic peptide 04 (cupiennin) family. 05 subfamily.